- Home
- VOXR vs ENTA Comparison
VOXR vs ENTA Comparison
Compare VOXR & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- ENTA
- Stock Information
- Founded
- VOXR 2014
- ENTA 1995
- Country
- VOXR United States
- ENTA United States
- Employees
- VOXR N/A
- ENTA N/A
- Industry
- VOXR Precious Metals
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- VOXR Basic Materials
- ENTA Health Care
- Exchange
- VOXR Nasdaq
- ENTA Nasdaq
- Market Cap
- VOXR 168.0M
- ENTA 164.6M
- IPO Year
- VOXR N/A
- ENTA 2013
- Fundamental
- Price
- VOXR $3.23
- ENTA $7.54
- Analyst Decision
- VOXR
- ENTA Buy
- Analyst Count
- VOXR 0
- ENTA 4
- Target Price
- VOXR N/A
- ENTA $18.00
- AVG Volume (30 Days)
- VOXR 860.4K
- ENTA 157.0K
- Earning Date
- VOXR 08-06-2025
- ENTA 08-04-2025
- Dividend Yield
- VOXR 1.53%
- ENTA N/A
- EPS Growth
- VOXR N/A
- ENTA N/A
- EPS
- VOXR N/A
- ENTA N/A
- Revenue
- VOXR $10,845,445.00
- ENTA $64,462,999.00
- Revenue This Year
- VOXR $16.51
- ENTA N/A
- Revenue Next Year
- VOXR $4.60
- ENTA $2.75
- P/E Ratio
- VOXR N/A
- ENTA N/A
- Revenue Growth
- VOXR N/A
- ENTA N/A
- 52 Week Low
- VOXR $2.21
- ENTA $4.09
- 52 Week High
- VOXR $3.79
- ENTA $16.06
- Technical
- Relative Strength Index (RSI)
- VOXR 46.91
- ENTA 56.12
- Support Level
- VOXR $3.13
- ENTA $6.44
- Resistance Level
- VOXR $3.39
- ENTA $8.23
- Average True Range (ATR)
- VOXR 0.14
- ENTA 0.46
- MACD
- VOXR 0.00
- ENTA -0.06
- Stochastic Oscillator
- VOXR 48.72
- ENTA 61.63
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.